Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours

Digestive and Liver Disease

Volumn 35, Issue 5, 2003, Pages 332-338

  Altimari, A ^a   Fiorentino, M ^a   Gabusi, E ^a   Gruppioni, E ^a   Corti, B ^a   D'Errico, A ^a   Grigioni, W F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ErbB1; ErbB2; Immunohistochemistry; Primary liver tumours

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEPATIC DUCT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; BILE DUCT TUMOR; GENE EXPRESSION REGULATION; INTRAHEPATIC BILE DUCT; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0142024103     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00077-X     Document Type: Article

References (36)

1. Tabor E. Hepatocellular carcinoma: global epidemiology. Dig Liver Dis 2001;33:118-20.
2. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001;28:503-13.
3. De Groen PC, Gores GJ, LaRusso N, Gundersson N, Nagorney DM. Biliary tract tumors. N Engl J Med 1999;341:1368-78.
4. Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 1992;13:125-31.
5. Bridges AJ. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999;6:825-43.
6. Kirshbaum MH, Yarden Y. The ErbB/HER family of receptor tyrosine kinases: a potential target for chemoprevention of epithelial neoplasms. J Cell Biochem Suppl 2000;34:52-60.
7. Sclichenmyer WJ, Fry DW. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Semin Oncol 2001;28(Suppl):67-79.
8. Todderud G, Carpenter G. Epidermal growth factor: the receptor and its function. Biofactors 1989;2:11-5.
9. Cadena DL, Gill GN. Receptor tyrosine kinases. FASEB J 1992;6:2332-7.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
11. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. HER2/neu expression in node negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
12. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl):9-15.
13. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000;60(Suppl 1):25-32.
14. Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001;37(Suppl):16-22.
15. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
16. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
17. Baselga J, Norton L, Albanell J, Kim JM, Mendelsohn J. Recombinant humanized anti HER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
18. Sliwkowski MX, Logfren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
19. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
20. Nakopoulou L, Stefanaki K, Filaktopoulos D, Giannopoulou I. C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Histol Histopathol 1994;9:677-82.
21. Hamazaki K, Yunoki Y, Tagashira H, Mimura T, Mori M, Orita K. Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev 1997;21:355-60.
22. Prange W, Schirmacher P. Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas. Oncol Rep 2001;8:727-30.
23. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377-83.
24. Hobday TJ, Alberts SR, De Groen PC, Burgart LJ, Roche PC, Sargent DJ, et al. Lack of C-ERBB-2 overexpression in carcinoma of the liver, gallbladder, and extrahepatic bile ducts. ASCO Meeting, New Orleans 2000; abstract 1063.
25. Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH, Su WC. Significance of c-erbB-2 expression in normal and neoplastic epithelium of the biliary tract. Anticancer Res 1995;15:1055-9.
26. Terada T, Ashida K, Endo K, Horie S, Maeta H, Matsunga Y, et al. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 1998;33:325-31.
27. Ito Y, Takeda T, Sasaki Y, Sakon M, Terumasa Y, Shingo I, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 2001;197:95-100.
28. Nonomura A, Ohta G, Nakanuma Y, Izumi R, Mizukami Y, Matsubara F, et al. Simultaneous detection of epidermal growth factor receptor (EGFR), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 1988;8:157-66.
29. Craig JR, Peters RL, Edmondson HA. Tumors of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology, Washington, DC: Armed Forces Institute of Pathology, 1988.
30. Snedecor GW, Cochran WG. Statistical methods. Ames, IA: Iowa State University Press, 1990.
31. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
32. Lee ET. Statistical methods for survival data analysis. New York: Wiley, 1992.
33. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000;19:177, abstract 686.
34. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
35. Musallam L, Ethier C, Haddad PS, Bilodeau M. Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 2001;280:G1360-9.
36. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase signaling module enhances DCA-induced apoptosis. Mol Biol Cell 2001;12:2629-45.